Ispecimen will serve as a preferred provider of cancer biospecimens

Woburn, massachusetts--(newsfile corp. - december 20, 2024) - ispecimen inc. (nasdaq: ispc), a leading online marketplace for human biospecimens, today announced its strategic initiatives for 2025, expanding services to procure high demand cancer biospecimens, enhancing its ability to support groundbreaking cancer research worldwide. the demand for cancer tissue continues to grow as cancer remains a significant area of focus in medical research and investment.
ISPC Ratings Summary
ISPC Quant Ranking